AbbVie: Hidradenitis Suppurativa trials

The registry lists 18 Hidradenitis Suppurativa studies with AbbVie as lead sponsor. 3 are open to participants now and 8 have results posted.

Phase 2 4Phase 3 6Phase 4 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis SuppurativaRecruitingNCT07136467
• A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of LutikizumabRecruitingNCT06524635Phase 2
• Expanded Access to UpadacitinibAvailableNCT04159597
• A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease SymptomsCompletedNCT04430855Phase 2Results posted
• A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT03926169Phase 2Results posted
• Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis SuppurativaCompletedNCT02904902Phase 3Results posted
• Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-SurgicallyCompletedNCT02808975Phase 4Results posted
• Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) PatientsCompletedNCT02739828Results posted
• Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis SuppurativaCompletedNCT01635764Phase 3Results posted
• Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis SuppurativaCompletedNCT01468233Phase 3Results posted
• Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis SuppurativaCompletedNCT01468207Phase 3Results posted
• A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06468228Phase 3
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyActive, not recruitingNCT05889182Phase 3
• A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic TherapyActive, not recruitingNCT05139602Phase 2
• Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis SuppurativaCompletedNCT03894956
• Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa SubjectsCompletedNCT03001115
• Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of IllnessCompletedNCT02896920
• Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life SettingCompletedNCT02786576